Navigation Links
ImpactRx Acquired by Symphony Technology Group

MOUNT LAUREL, N.J., April 18, 2011 /PRNewswire/ -- ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, announced today that Symphony Technology Group (STG), has acquired a majority ownership interest in the Company. STG is a leading private equity firm with a strategic focus on data, analytics and technology-enabled services companies. Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx's existing investors, will maintain its investment in ImpactRx. Under the terms of the acquisition, ImpactRx will operate as an independent STG portfolio company.  Current President and CEO, Richard Altus, will continue to lead ImpactRx.  Financial terms of the transaction were not disclosed.

"Symphony Technology Group's mission is to invest in companies with a compelling set of assets and capabilities, and solid client relationships, and work closely with management to deliver innovative solutions to customers and increase company growth," said J.T. Treadwell, Managing Director with STG. "We have nearly a decade of experience partnering with our companies to leverage data, technology, and analytics to deliver breakthrough insight for customers and to expand operations in a cost-effective, timely and thoughtful fashion." ImpactRx is a strong company, and a terrific starting point for STG to bring its operations-focused approach to investing in the life sciences industry. We are pleased that Merck Capital Ventures shares our vision as a shareholder committed to ImpactRx's future."

"We are delighted to be joining forces with Symphony Technology Group," declared Richard Altus, ImpactRx's President and CEO.  "STG has a very strong track record of working with companies to improve execution through leveraging technologies and best-in-class data analytics in other industries. STG will help ImpactRx to improve as a leader in evaluating and interpreting the drivers of physician behavior, as well as help us expand our reach and scope as a partner to our customers," Altus stated.

"Brand teams are facing increasingly complex challenges; understanding what drives brand performance, through all stages of the life cycle, is more critical today than it ever was," continued Altus. "The acquisition and investment by STG will allow us to further develop our unique capabilities to better respond to our clients' emerging information and analytical needs. In addition, integrating our proprietary syndicated data set with external secondary and custom data resources, leveraging STG's vast data modeling and analytics expertise, will enable us to deliver the comprehensive, multi-channel solutions our clients need to grow their businesses in today's complicated and competitive biopharmaceutical marketplace," said Altus.

STG companies are known for providing high value, high-impact solutions that help customers dramatically improve their performance, productivity and profitability through best-in-class processes and management.

About ImpactRx

Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx's longitudinal panels of high value, iPhone-connected physicians are the exclusive source of continuously-captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx leverages this unprecedented intelligence with custom research and analytics to provide insightful solutions to pharmaceutical marketing and sales decision makers. For more information, visit:

About Symphony Technology Group –

Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformation expertise to enable its companies to deliver maximum value to their clients, to drive growth through innovation, to retain and attract the best talent and to achieve best in class business performance. STG's current portfolio consists of ten global companies. For more information, visit:

Jennifer Aguilar
Sagefrog Marketing Group, LLC

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
3. ImpactRx Releases 2010 Oncology Promotion Report
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
7. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
8. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
9. Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections
10. FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
11. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
Post Your Comments:
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):